GERNHealthcare · BiotechnologyThe 5 Wall Street analysts covering Geron Corp. hold a median 12-month price target of $3.5 — +291.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Geron Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GERN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +291.3% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Wedbush | Maintains | Outperform | $6.00 → $5.00 |
| 28 Oct 2026 | Needham | Maintains | Buy | $4.00 → $2.50 |
| 5 Nov 2025 | Needham | Maintains | Buy | $5.00 → $4.00 |
| 5 Nov 2025 | Needham | Maintains | Buy | — |
| 10 July 2025 | Goldman Sachs | Reinstates | Sell | $1.00 |
| 8 May 2025 | Scotiabank | Downgrade | Sector Perform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Mar 2025 | Needham | Reiterates | Buy | — |
| 27 Feb 2025 | Barclays | Maintains | Overweight | — |
| 27 Feb 2025 | Needham | Maintains | Buy | — |
| 27 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 27 Feb 2025 | Stifel | Maintains | Buy | — |
| 26 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 18 Feb 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Jan 2025 | Needham | Maintains | Buy | — |
| 13 Dec 2024 | Needham | Reiterates | Buy | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Oct 2024 | Scotiabank | Initiates | Sector Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GERN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Geron Corp. returned −27.9% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 42% of US stocks
Cheaper than 34% of US stocks
Cheaper than 87% of US stocks
Higher than 66% of US stocks
Higher than 56% of US stocks
Higher than 93% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 28% of US stocks
Higher than 33% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Geron Corp. has a market value of $574.6M and an enterprise value of $429.2M.
Revenue in the twelve months to 30 June 2026: $204.6M. The latest quarter grew 17.2% year on year.
Net income over the same four quarters: −$67.6M, a −33.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.11.
Free cash flow in the twelve months to 30 June 2026: −$114.8M.
Trailing P/E: −6.9×; forward P/E: 22.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Geron Corp. employs 258 people — $793K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Geron Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Geron halted its late-stage cancer program. Its shares fell on Wednesday following the announcement.
Why it matters — GERN watchers may note the halt to the company's late-stage cancer program and the reported share decline.
Geron said Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
Why it matters — The decision affects a late-stage clinical trial of a Geron treatment for rare blood cancer.
Geron announced it will discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, following a recommendation from the independent Data Monitoring Committee.
Why it matters — The decision affects a Phase 3 clinical trial of one of Geron’s therapies.
Geron said it will release its third-quarter 2026 financial results and business highlights before the market opens on November 4, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time.
Why it matters — GERN watchers can look to the scheduled release and call for the company’s quarterly results and business update.
Geron reported that, effective October 16, 2026, it granted stock options to purchase 570,000 shares of common stock to three newly hired employees. The grants were inducements for the employees to accept employment with the company.
Why it matters — A GERN watcher may note the reported equity grants as part of the company’s hiring and compensation disclosures.
The 5 Wall Street analysts covering Geron Corp. have a median 12-month price target of $3.5, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Geron Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Geron Corp. 49 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Geron Corp. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +291.3% from the last close, and Ticker Nerd's factor model ranks Geron Corp. 49 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Geron Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GERN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.
Geron Corp. returned -27.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.
The most recent item we track (Benzinga, 28 Oct 2026): "Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth". Geron halted its late-stage cancer program. Its shares fell on Wednesday following the announcement.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. The company’s work centers on oncology programs that target abnormal blood-forming cells, with an emphasis on myeloid malignancies and other disorders of the bone marrow and blood. Geron Corporation serves the specialized hematology-oncology market by advancing targeted treatment options for patients with limited alternatives, supporting use across clinical practice, specialty care settings, and disease-focused treatment centers. Headquartered in Foster City, California, Geron Corporation is positioned as a focused biotechnology company built around telomerase inhibition and commercial therapy development.
CEO Mr. Harout Semerjian · 258 employees · United States · https://www.geron.com
